Answers are grounded in this paper and cite their sources.
Background Afatinib is a first-line option for non-small cell lung cancer (NSCLC) with uncommon epidermal growth factor receptor (EGFR) mutations, but the optimal starting dose remains unclear, particularly in Southeast Asian populations. We compared clinical outcomes of a reduced 30 mg starting dose versus the standard 40 mg dose. Methods We retrospectively analyzed 78 patients with uncommon EGFR-mutated NSCLC (59 started at afatinib 30 mg/day, 19 at 40 mg/day) at Vietnam National Cancer Hospital (2018–2024). The starting dose was selected by the treating physician, and subsequent dose adjustment was permitted. Primary endpoints were progression-free survival (PFS) and objective response rate (ORR); secondary endpoints were disease control rate (DCR), overall survival (OS), and safety. Median follow-up was 19.7 months. Results ORR was 67.8% (30 mg) versus 63.2% (40 mg; p = 0.782); DCR was 86.4% versus 68.4% (p = 0.092). Median PFS was 10.9 vs 11.4 months (hazard ratio [HR] for 40 mg vs 30 mg, 0.88; 95% confidence interval [CI] 0.48–1.63; p = 0.688); median OS was 25.5 vs 23.1 months (HR 1.06, 95%CI 0.50–2.24; p = 0.881). Diarrhea (57.7%), rash (50.0%), and paronychia (28.2%) were the most common adverse events. Any-grade diarrhea occurred in 57.6% (30 mg) and 57.9% (40 mg) (p = 1.000). Grade ≥3 diarrhea (3.4% vs 15.8%; p = 0.090) and any grade ≥ 3 toxicity (8.5% vs 15.8%; p = 0.395) were numerically less frequent with 30 mg, but neither difference was statistically significant; any-grade toxicity was similar (84.7% vs 89.5%). Dose reduction at any time was less frequent with 30 mg (11.9% vs 42.1%; p = 0.007); among only the patients who underwent a reduction (n = 6 vs n = 8 with a recorded date), the median time to first reduction was 141 vs 39 days. In the 30 mg group, 12 patients escalated to 40 mg. Conclusion In this retrospective cohort, no statistically significant differences in ORR, DCR, PFS, or OS were observed between afatinib starting doses of 30 mg and 40 mg, and overall toxicity was similar. A 30 mg starting dose was associated with fewer dose reductions, which does not by itself indicate a superior safety profile. Prospective studies are needed to define the optimal starting dose in patients with uncommon EGFR mutations, particularly in lower body size and in settings with limited toxicity monitoring.
No takes yet. Share an insight, caveat, or question.
Anh et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: